Date de publication : 11 juillet 2022

Inactivation of TIGIT and/or PDCD1 gene in melanoma-specific CD8+ T lymphocytes


Découvrez les projets de l’équipe 3

DARVAC: Inserm impact Santé

DARVAC: Inserm impact Santé

Team 3 from INCIT Lab Inserm U1302 (Nantes) is part of the Inserm Impact Santé project DARVAC "Development of vaccines offering innovative early protection against non-viral cancers" based on ghost (Dark) proteins. The project is led by Jerome Galon, with Michel...

lire plus